Vitrolife AB: Interim report Q3, 2026

Vitrolife AB reported Q3 2026 sales of SEK 884 million, up from SEK 835 million a year earlier. Organic growth was 6% in local currencies, excluding the exited NACE and GPDx product lines; total growth was 4% in local currencies and 6% in SEK. Growth was primarily driven by the Technologies segment.